GLPwatch
In adults with overweight or obesity, continued weekly semaglutide after a 20-wk run-in improved weight loss.
Ann Intern Med · 2021
Last updated 2026-05-28In a study of 1,961 adults with overweight or obesity, participants who took weekly semaglutide for 48 weeks after a 20-week initial treatment period lost an average of 17.4% of their body weight, compared to 2.6% in those who switched to a placebo after the initial period.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2021 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.13 |
| NIH percentile | 9 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Abstract
Rubino D, Abrahamsson N, Davies M, et al. JAMA. 2021;325:1414-25. 33755728.
Verbatim abstract via PubMed 34339232 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.